E-mail: info@almedis.ru
Tel: +7 495 937 43 18
Fax: +7 495 937 43 19
Address: 5, Ulitsa Malaya Pirogovskaya, office 22
119435 Moscow, Russia

RUS ENG
About Us
Our Services
Quality
Contact Us
News
Links
Career

Year 2017 (Hide...)

March’17
  • ALMEDIS has performed one-day training “Using of PRO and Health Measurement Scales in Clinical Trials” for a corporate client.
  • ALMEDIS has performed two-day training “New Trends in Rare Diseases Clinical Research – Endpoints, Designs and Statistical Analysis” for a corporate client.
  • 350 patients have been recruited in 20 Russian sites in an international multicenter Phase III clinical trial in patients with acute coronary syndrome receiving antiplatelet therapy after pharmacological thrombolysis.
  • ALMEDIS has performed feasibility analysis for Russia and Baltic States for a multinational Phase II clinical trial in adult patients with moderate and severe psoriasis.
February’17
  • ALMEDIS has received an approval of the Ministry of Health of Russia for a Phase II clinical trial of a combination of antiviral drugs in treatment-naïve patients with chronic hepatitis C.
  • LPLV milestone has been achieved in the Extension Phase of an international multicenter Phase III clinical trial in patients with chronic hepatitis C.
  • Study Protocol has been prepared for a non-interventional study in patients with type 2 diabetes mellitus.
January’17
  • ALMEDIS has initiated start-up activities for a new multinational multicentre pilot clinical trial in patients with prostate cancer.
  • ALMEDIS has received an approval of the Ministry of Health of Russia for a drug interaction Phase I clinical trial of an antiviral drug. 
  • Data collection has been completed in Russia for an international study in patients on chronic hemodialysis.

 

Year 2016 (Read...)

Year 2015 (Read...)

Year 2014 (Read...)

Year 2013 (Read...)

Year 2012 (Read...)

Year 2011 (Read...)

Year 2010 (Read...)

Year 2009 (Read...)

Year 2008 (Read...)

 

ALMEDIS is solely responsible for this site content. This information is intended for use by our customers and clinical research specialists.
© 2006-2017 ALMEDIS All rights reserved